CAMBRIDGE, Mass. — Enveric Biosciences said it has been granted a new U.S. patent that expands the scope of its intellectual property portfolio and increases the number of molecules the company may develop or license for the treatment of neuropsychiatric conditions.
The newly issued U.S. Patent No. 12,492,179, titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives,” includes claims covering compositions and methods of treatment for novel molecules with potential applications in mental health disorders. Company officials said the patent strengthens protection around Enveric’s pipeline of neuroplastogenic and non-hallucinogenic small-molecule candidates.
According to the company, the patent broadens its ability to pursue treatments targeting neuropsychiatric, neurological, and addiction-related disorders, particularly in areas with limited therapeutic options. The expanded set of protected molecules may also create additional opportunities for licensing and partnerships with pharmaceutical companies active in the neuropsychiatric space.
Enveric said strong intellectual property protection is a critical factor for advancing drug candidates through full clinical development, particularly for large pharmaceutical partners seeking a viable return on investment. Composition-of-matter protection, such as that provided under the newly issued patent, is considered one of the most robust forms of intellectual property protection for novel therapeutics.
The molecules covered by the patent are based on known compounds with established pharmacological activity and have been chemically modified to potentially improve efficacy and reduce side effects compared with existing treatments. The company said these modifications could result in drug candidates with performance profiles that surpass currently available therapies for neuropsychiatric conditions.
“Enveric’s growing pipeline of patented molecules expands the available opportunities to develop next-generation treatments for neuropsychiatric conditions, leveraging our innovative research,” said Joseph Tucker, Ph.D., director and chief executive officer of the company. “As our intellectual property footprint and portfolio of patented molecules expand, the impact of our efforts is crystallizing into a significant position within the industry, providing the company with a compelling future to pursue.” (Source: IANS)
